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Abstract  
Introduction: The aim of the study was to reveal the mechanisms for the 
pathogenesis and progression of type 1 diabetes mellitus (T1DM).  
Material and methods: Two mRNA expression profiles and two miRNA expression 
profiles were downloaded from the Gene Expression Omnibus (GEO) database. The 
differentially expressed genes (DEGs), differentially expressed miRNAs (DEMs), 
functional enrichment analyses, pathways, putative targets for DEMs and the 
miRNA-gene pairs, protein-protein pairs of DEGs, and PPI network were constructed. 
Results: Based on mRNA expression profiles, 37 and 110 DEGs were identified, and 
named as DEGs-short and DEGs-long, respectively. Based on miRNA expression 
profiles, 15 and six DEMs were identified, and named as DEMs-short and DEMs-long, 
respectively. DEGs-short were enriched in six GO terms and four pathways, and 
DEGs-long enriched in 40 GO terms and 10 pathways. Seventeen miRNA-gene pairs 
for DEMs-short were screened out; hisa-miR-181a and hisa-miR-181c were involved 
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in the most pairs. Twenty pairs for DEMs-long were obtained; hsa-miR-338-3p was 
involved in all the pairs. KLRD1 was involved in more pairs in the network of 
DEGs-short. ACTA2 and USP9Y were involved in more pairs in the network of 
DEGs-long. Conclusions: KLRD1, hisa-miR-181a, and hisa-miR-181c might be 
pathogenic biomarkers for T1DM, ACTA2, USP9Y, and hsa-miR-338-3p progressive 
biomarkers of T1DM. 
Key words: type 1 diabetes mellitus (T1DM); pathogenesis; progression; 
transcriptome analysis 
 
Introduction  
Diabetes mellitus (DM) is a group of metabolic disorders in which there are high 
blood sugar levels over a prolonged period. It is established that 415 million people 
had DM worldwide in 2015, and the number is predicted to reach more than 642 
million by 2040 [1]. Moreover, from 2012 to 2015, approximately 1.5 to 5.0 million 
deaths each year resulted from DM [2]. DM is divided into three main types: Type 1 
DM (T1DM), type 2 DM (T2DM), and gestational diabetes. Type 1 DM results from 
the pancreas’s failure to produce enough insulin and makes up an estimated 5–10% of 
all diabetes cases [3]. The classical symptoms are frequent urination, increased thirst, 
increased hunger, and weight loss. At present, the cause of T1DM is still unknown, 
and genetic susceptibility, a diabetogenic trigger, and high exposure to an antigen are 
believed to be involved [4]. A meta-analysis involving 2238 T1DM participants 
showed that individuals had a higher risk for T1DM with the G allele of CTLA-4 
+49A/G gene polymorphism [5]. Arroyo-Jousse et al. [6] found that T1DM patients 
showed a higher TNFa gene promoter methylation compared with control subjects 
[P=0.00008]. A study of genome-wide gene expression analysis revealed that CD274 
up-regulation in T1DM is correlated with the pathogenesis [7]. MicroRNA (miRNAs) 
are involved in various biological processes and become novel biomarkers in DM. A 
miRNA expression profile analysis showed that eight circulating miRNAs were 
dysregulated in T1DM patients (miR-21-5p, miR-146a-5p, miR-148a-3p, 
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miR-181a-5p, miR-210-5p, miR-342-3p, miR-375, and miR-1275), which might be 
potential circulating biomarkers of this disease [8]. Moreover, a single-nucleotide 
polymorphism (rs2910164) in the miRNA-146a gene is significantly associated with 
diabetic nephropathy in T1DM patients [9]. 
Transcriptomics technologies are the techniques used to study an organism’s 
transcriptome, the sum of all of its RNA transcripts. Among them, mRNA conveys 
genetic information from DNA to the ribosome, and miRNA functions in RNA 
silencing and post-transcriptional regulation of gene expression [10]. Transcriptomic 
analysis can study gene expression changes in different organisms, which contribute 
to the understanding of human disease [11]. In this study, the transcriptomic analyses 
were performed on new-onset and long-term T1DM patients in order to reveal the 
mechanisms for the pathogenesis and progression of this disease. 
 
Material and methods 
Expression profiles 
The expression profiles of GSE55098 [12], GSE72492, GSE55099, and GSE97123 
[13] were downloaded from the Gene Expression Omnibus (GEO) database 
(www.ncbi.nlm.nih.gov/geo/). The mRNA expression profile of GSE55098 contained 
22 peripheral blood mononuclear cell (PBMC) samples from 12 newly diagnosed 
T1DM patients and 10 normal controls, and it was detected using the platform of 
[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. The mRNA 
expression profile of GSE72492 included 17 pancreas tissue samples from T1DM 
patients and seven healthy humans, and these patients had been suffering from T1DM 
for at least five years. Agilent-028004 SurePrint G3 Human GE 8x60K Microarray 
was used to conduct the detection for GSE72492. Twelve PBMC samples from newly 
diagnosed T1DM patients and 10 PBMC samples from normal controls were 
contained in the miRNA expression profile of GSE55099, and they were sequenced 
with the platform of miRNA-1 Affymetrix Multispecies miRNA-1 Array. Twenty-four 
plasma-derived exosomes from 12 T1DM patients and 12 healthy patients were 
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concluded in the miRNA expression profile of GSE97123, and these patients had 
suffered from T1DM for at least 25 years. The detection platform for GSE97123 was 
Counter Human miRNA Expression Assay. 
 
Data processing 
For GSE55098 and GSE55099, background correction, standardisation, and 
expression value calculation for the raw data were conducted with the affy V1.48.0 
package (http://www.bioconductor.org/packages/3.2/bioc/html/affy.html). The 
hgu133plus2.db package V3.2.2 
(http://www.bioconductor.org/packages/3.2/data/annotation/html/hgu133plus2.db.htm
l) was used to annotate, and the non-annotated probes were removed. For GSE72492, 
standardisation and logarithm calculation of expression values were performed with 
preprocessCore V1.32.0 
(http://www.bioconductor.org/packages/3.2/bioc/html/preprocessCore.html). For 
GSE97123, the downloaded raw data had been normalised, and logarithm calculation 
was directly conducted.  
 
Differentially expressed analysis 
Based on the mRNA and miRNA profiles of GSE55098 and GSE55099, the 
differentially expressed genes (DEGs) and the differentially expressed miRNAs 
(DEMs) were separately identified in samples from newly diagnosed T1DM patients 
compared with those from normal controls with limma V3.32.2 
(http://www.bioconductor.org/packages/3.5/bioc/html/limma.html), which were 
named as DEGs-short and DEMs-short, respectively. Furthermore, the DEGs and the 
DEMs were separately identified in samples from longstanding T1DM patients 
compared with those from healthy people in GSE72492 and GSE97123, and named as 
DEGs-long and DEMs-long, respectively. The threshold criteria was |log (fold 
change)| > 1 and P < 0.05. 
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Functional and pathway enrichment analyses of DEGs 
The functional enrichment analyses of the DEGs-short and DEGs-long were 
performed via the Database for Annotation, Visualisation, and Integrated Discovery 
(DAVID) V6.8 (http://david.abcc.ncifcrf.gov/). The enriched pathway terms were 
screened out with the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
PATHWAY (http://www.genome.jp/kegg), and Reactome (http://www.reactome.org). 
The threshold was P < 0.05. 
 
Targets prediction for DEMs 
Potential targets for DEMs-short and DEMs-long were predicted by > 5 
bioinformatics algorithms among the 10 algorithms in the miRWalk database: 
miRWalk V2.0 (www.ma.uni-heidelberg.de/apps/zmf/mirwalk/mirwalk), RNAhybrid 
V2.1 (www.ma.uni-heidelberg.de/apps/zmf/mirwalk/rnahybrid), DIANAmT V4.0 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/diana-microt), miRanda -rel2010 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/miranada), miRDB V4.0 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/mirdb), PICTAR4 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pictar4), PICTAR5 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pictar5), PITA 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/pipa), RNA22 V2 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/rna22), and Targetscan V6.2 
(www.ma.uni-heidelberg.de/apps/zmf/mirwalk/targetscan). Moreover, the negative 
regulated miRNA-gene pairs were selected out.  
 
The PPI network construction 
The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) is a 
biological database and web resource of known and predicted protein-protein 
interactions (PPI). The protein-protein pairs of DEMs-short and DEMs-long were 
identified via STRING v10.5 (https://string-db.org/) with more than 500 scores. 
Afterwards, the PPI networks for DEGs-short and DEGs-long were constructed and 
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visualised by Cytoscape V3.5.1 software (http://www.cytoscape.org/download.php).  
 
Results 
DEGs and DEMs 
After differentially expressed analysis, 37 (25 up- and 12 down-regulated) and 110 
(58 up- and 52 down-regulated) DEGs were identified in sets of DEGs-short and 
DEGs-long, respectively; and 15 (two up- and 13 down-regulated) and six (one up- 
and five down-regulated) DEMs were identified in sets of DEMs-short and 
DEMs-long, respectively. Furthermore, the top 30 most significant DEGs of 
DEGs-short and DEGs-long are separately shown in Table 1A and Table 1B, and all 
the DEMs of DEMs-short and DEMs-long are shown separately in Table 2A and 
Table 2B. Also, the overlaps of DEGs-short and DEGs-long were EIF1AY, LTF, and 
DDX3Y, and there was no overlap between DEMs-short and DEMs-long. 
 
The enriched gene ontology (GO) terms and pathways 
DEGs-short and DEGs-long were separately enriched in six and 40 GO terms, and all 
the GO terms of DEGs-short and the top 10 most significant terms of DEGs-long are 
shown in Table 3A and Table 3B, respectively. Moreover, DEGs-short were enriched 
in four pathway terms, namely “graft-versus-host disease”, “antigen processing and 
presentation”, “natural killer cell mediated cytotoxicity”, and “signalling in immune 
system”. DEGs-long were enriched in 10 pathways; namely, “smooth muscle 
contraction”, “vascular smooth muscle contraction”, “regulation of insulin-like 
growth factor (IGF) transport and uptake by insulin-like growth factor binding 
proteins (IGFBPs)”, “cGMP-PKG signalling pathway”, “RHO GTPases activate 
PAKs”, “platelet degranulation”, “insulin processing”, “chemical carcinogenesis”, 
“antagonism of activin by follistatin”, and “insulin secretion”. 
 
The miRNA-gene pairs 
A total of 17 miRNA-gene pairs were screened out for DEMs-short, and they are 
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shown in Table IVA, including nine negatively regulated pairs. Moreover, 
hisa-miR-181a and hisa-miR-181c were involved in the most pairs. Twenty 
miRNA-gene pairs in total were screened out for DEMs-long (Tab. IVB), including 11 
negatively regulated pairs. Also, hsa-miR-338-3p was involved in all the above 20 
miRNA-gene pairs. 
 
The PPI network 
After STRING screening, 19 and 89 protein-protein pairs of DEGs-short and 
DEGs-long were separately obtained, and the PPI networks of them are shown in 
Figure 1 and 2, respectively. The above pairs were a clustered different functional 
group in the networks, and KLRD1 (dark red) was involved in more pairs in a 
functional group of Figure 1, and ACTA2 and USP9Y (dark red) were involved in 
more pairs in different functional groups of Figure 2. 
 
Discussion 
Many genes and miRNAs have been indicated to be involved in the occurrence and 
development of T1DM. In this study, we parallelly identified and analysed the 
differential expressions for newly diagnosed and long-standing T1DM patients. 
Afterwards, hisa-miR-181a and hisa-miR-181c were found to be involved in the most 
miRNA-gene pairs of DEMs-short (Tab. IVA), and the node of KLRD1 was involved 
in the most pairs in the PPI network of DEGs-short (Fig. 1). A meta-analysis showed 
that the hsa-miR-181 family are involved in the inhibition of IL-2 expression, and 
hisa-miR-181a and hisa-miR-181c contribute to T cell tolerance, which is very 
important in the pathogenesis and treatment of T1DM [14, 15]. Also, the 
meta-analysis also proved that hsa-miR-181c was differentially expressed in the three 
types of diabetes (T1DM, T2DM, and gestational diabetes). Another study found that 
hsa-miR-181c was down-regulated in a diabetic-like environment and up-regulated 
after the addition of calcitriol [16]. Endothelial dysfunction played an important role 
in the occurrence and development of DM, and hisa-miR-181c could attenuate 
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nitration stress through regulating FoxO1 expression and affecting endothelial cell 
function [17]. It might be one of the mechanisms of hisa-miR-181c in the occurrence 
and development of DM. Killer cell lectin-like receptor subfamily D, member 1 
(KLRD1), encoded by KLRD1 gene, is an antigen preferentially expressed on NK 
cells, and also known as cluster of differentiation 94 (CD94). Nakata et al. [18] 
reported that the expression of KLRD1 was reduced in NK-enriched cells in fulminant 
T1DM. Goodier et al. [19] reported that there was a significant reduction in the 
proportion of CD94 (+) cells responding to lipopolysaccharide in T1DM compared to 
the non-diabetic twin (p = 0.025), which might be associated with the cause of T1DM. 
Therefore, we suspected that KLRD1, hisa-miR-181a, and hisa-miR-181c were novel 
biomarkers in the pathogenesis of T1DM. Also, this article identified some targets for 
hisa-miR-181a and hisa-miR-181c, such as KCNJ2, DDX3Y, KLRF1, IFNG, etc. (Tab. 
IVA).  
Furthermore, our results showed that hsa-miR-338-3p was involved in all the 
miRNA-gene pairs of DEMs-long (Tab. IVB). The PPI network of DEGs-long was 
clustered different functional groups, and ACTA2 and USP9Y were involved in more 
pairs in different functional groups (Fig. 2). Jacovetti et al. [20] found in rodents that 
β cell mass expansion during pregnancy and obesity is associated with the expression 
change of hsa-miR-338-3p; they also revealed a major role for hsa-miR-338-3p in 
compensatory β cell mass expansion occurring under different insulin resistance states. 
Subsequently, Nesca et al. [21] reported that the expression hsa-miR-338-3p displayed 
changes occurring before the onset of diabetes, which were positive effects on β cell 
activities and mass; in contrast, modification in the level of hsa-miR-338-3p primarily 
occurred in diabetic mice and resulted in increased β cell apoptosis. These results 
indicate that the expression change of hsa-miR-338-3p participates in the progression 
of diabetes. Alpha-actin-2 (α-SMA) is a protein encoded by the ACTA2 gene, which 
is commonly used as a marker of myofibroblast formation [22]. ACTA2 is the human 
aortic smooth muscle actin gene and is involved in cell motility, structure, and 
integrity [23]. Moreover, DEGs-long was enriched in GO terms of “contractile fibre”, 
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“smooth muscle contractile fibre”, “actomyosin structure organisation”, “myofibril”, 
and “cardiac muscle tissue development” (Tab. IIIB), and ACTA2 played very 
important roles in the above GO terms. Although few reports revealed the relationship 
between ACTA2 and T1DM, our results suggest that ACTA2 is associated with the 
progression of this disease. USP9Y gene encodes the enzyme of ubiquitin specific 
peptidase 9, Y-linked (USP9Y), which locates on the Y chromosome. Mutations in 
this gene are associated with Sertoli cell-only syndrome (SCO) and male infertility. 
The gene fusion TTTY15-USP9Y score was statistically significantly higher in 
prostate cancer men with positive biopsy outcome than in men with negative biopsy 
outcome (p < 0.001), and thus TTTY15-USP9Y could be used to predict biopsy 
outcome [24]. USP9Y presents only in black people of African origin and attributes a 
favourable lipoprotein pattern, which is very important in the development of diabetes 
[25]. Previously, there was no direct evidence that USP9Y is associated with TIDM. 
Here, our article found that USP9Y occupied a critical position in the PPI network of 
DEGs-long, which suggested that USP9Y might play a role in the development of 
T1DM. 
 
Conclusion 
In conclusion, our study suggested that KLRD1, hisa-miR-181a, and hisa-miR-181c 
were involved in the onset of T1DM, and that ACTA2, USP9Y, and hsa-miR-338-3p 
played some important roles in its development. They are potential biomarkers in the 
pathogenesis or progression of T1DM, which provides further insights for T1DM. 
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Figure 1. The protein–protein interaction (PPI) network of DEGs-short 
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Figure 2. The protein–protein interaction (PPI) network of DEGs-long 
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Table IA. The top 30 most significant differentially expressed genes (DEGs) in 
peripheral blood mononuclear cell samples from newly diagnosed patients with type 1 
diabetes mellitus (T1DM) compared with those from normal controls (DEGs-short) 
Gene 
LogF
C 
AveE
xpr 
p 
value 
Gene LogFC 
AveEx
pr 
p value 
CD16
0 
 
–1.4857408
17 
9.3754
68318 
5.04E 
–06 
CMT
M2 
1.4308
1945 
8.18768
1273 
0.006335
067 
KLR
D1 
 
–1.1272781
8.9419
06288 
1.10E 
–05 
KCN
J2 
1.0778
69083 
6.54747
9591 
0.006475
015 
 15 
 
89 
CCL4 
 
–1.2661478
83 
10.580
44818 
1.64E 
–05 
CHI3
L1 
1.1924
713 
5.11561
4424 
0.007671
493 
GNL
Y 
 
–1.1445241
17 
12.248
86857 
3.63E 
–05 
CYP
4F3 
1.8331
72833 
5.90927
4955 
0.008561
103 
GZM
H 
 
–1.1788713
5 
11.650
18586 
4.33E 
–05 
S100
P 
1.6346
46917 
8.56842
1091 
0.012775
649 
CLIC
3 
 
–1.1797844
83 
9.1449
89091 
6.78E 
–05 
KRT
23 
1.5157
19783 
5.29823
6045 
0.014109
852 
KLR
F1 
 
–1.0007149
33 
10.694
16009 
0.0001
17664 
CRIS
P3 
1.1013
3205 
4.73427
1773 
0.020811
07 
FGF
BP2 
 
–1.1626733
5 
11.117
17164 
0.0001
95317 
SLPI 
1.3870
85033 
6.38005
0636 
0.022275
293 
KLR
C3 
 
–1.2678662
17 
8.3827
17909 
0.0002
56813 
TNF
AIP6 
1.3640
51308 
5.90321
6886 
0.022326
902 
HLA 
–DQA1 
 
–1.7812468
5.7141
09242 
0.0016
18603 
CEA
CAM8 
1.8222
26467 
7.05893
0909 
0.026668
873 
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5 
DUS
P2 
 
–1.2895842
17 
8.9455
54227 
0.0018
57457 
LTF 
1.4074
60333 
9.77583
1136 
0.029817
392 
CCR
3 
1.2143
28983 
6.7909
13364 
0.0024
97141 
RET
N 
1.0505
59983 
8.87528
7318 
0.030854
117 
IFNG 
 
–1.0604171
67 
7.4995
63636 
0.0046
50993 
MM
P9 
1.1853
83167 
7.67172
0636 
0.030963
045 
FFA
R2 
1.6261
23483 
5.8583
63545 
0.0049
65728 
PGL
YRP1 
1.0023
44033 
6.66258
0909 
0.032331
45 
MS4
A3 
1.2222
84567 
8.3454
52523 
0.0060
33224 
RNA
SE3 
1.3085
789 
7.11336
3909 
0.034102
172 
Table IB. The top 30 most significant differentially expressed genes (DEGs) in 
pancreas tissue samples from long-standing patients with type 1 diabetes mellitus 
(T1DM) compared with those from healthy people (DEGs-long) 
Gene LogFC 
AveEx
pr 
p 
value 
Gene LogFC 
AveExp
r 
p value 
INS 
 
–7.95640929
4 
11.805
39147 
1.61E 
–07 
SYT
7 
 
–1.0300685
36 
7.62679
6818 
0.000343
623 
IAPP 
 
–4.97388763
8.7485
84024 
6.19E 
–07 
ANG
PT2 
1.1488
73747 
7.08668
0079 
0.000482
281 
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4 
SSC4
D 
 
–1.07559744
7 
10.207
99228 
1.77E 
–06 
EIF1
AY 
1.0837
9585 
7.04679
1771 
0.000545
989 
CHST
8 
 
–1.17593256
4 
7.5823
15976 
2.88E 
–06 
HSP
B2 
1.1040
37749 
8.50365
4391 
0.000556
139 
INS-I
GF2 
 
–3.23222547
3 
6.5330
42141 
3.07E 
–06 
SLC2
5A34 
 
–1.7282471
11 
10.1113
3012 
0.000591
585 
PHYH
IPL 
1.18534
172 
7.2527
59135 
1.51E 
–05 
CCD
C3 
1.0589
4566 
9.65593
0312 
0.000628
911 
GCGR 
 
–1.70586376 
6.8277
50629 
2.11E 
–05 
PTGI
S 
1.4248
89976 
8.26025
5438 
0.000790
294 
SLC3
5D3 
 
–1.67984228
9 
6.6563
38606 
2.39E 
–05 
DDX
3Y 
1.9922
55074 
6.24894
3021 
0.000831
372 
G6PC
2 
 
–2.11681348
7 
6.1128
31353 
3.10E 
–05 
SLC3
0A8 
 
–1.4942758
89 
9.14196
8897 
0.000835
193 
SYT1
3 
 
–1.66289816
7 
8.2092
65965 
3.21E 
–05 
RPS4
Y1 
5.3417
7196 
8.27552
28 
0.000839
019 
 18 
 
EPN3 
 
–1.01473930
4 
8.7157
85241 
6.32E 
–05 
UTY 
1.4284
51427 
5.67249
7188 
0.000859
705 
VEGF
C 
1.18662
2956 
8.3087
87518 
0.0001
2934 
CCL
21 
2.1035
7751 
8.79913
6812 
0.000869
965 
CELF
4 
 
–1.04963823
4 
8.2607
41659 
0.0001
38073 
FAM
159B 
 
–1.6854862
41 
7.29398
4476 
0.000950
918 
ADC
YAP1 
 
–1.22968926
3 
5.7114
79118 
0.0001
53888 
UCH
L1 
 
–1.2057102
31 
9.84709
2909 
0.000976
663 
PCSK
1 
 
–1.97980276
2 
8.4732
64497 
0.0002
27194 
RPS4
Y2 
5.2640
40346 
8.25160
6735 
0.001024
289 
 
Table IIA. All the differentially expressed miRNAs (DEMs) in peripheral blood 
mononuclear cell samples from newly diagnosed patients with type 1 diabetes 
mellitus (T1DM) compared with those from normal controls (DEMs-short) 
Gene LogFC  AveExpr p value 
hsa-miR-28-3p  –1.928257799 2.792230233 2.80E-06 
hsa-miR-146b-5p  –2.666591212 4.4375168 1.12E-05 
hsa-miR-181a-2  –1.887221452 2.705472828 6.15E-05 
 19 
 
hsa-miR-28-5p  –1.383941091 3.923182481 6.17E-05 
hsa-miR-1225-3p 1.023616193 1.73814695 9.27E-05 
hsa-miR-181c  –1.26274394 2.593748088 0.000439044 
hsa-miR-1249 1.091444886 2.36209401 0.000543799 
hsa-miR-199a-5p  –1.287916775 1.850112207 0.000747813 
hsa-miR-125b  –1.075210791 1.90891557 0.000922042 
hsa-miR-19b  –1.14946891 5.355734538 0.001454218 
hsa-let-7f  –1.664920459 5.356012127 0.001554297 
hsa-miR-487b  –1.334061912 2.992923132 0.012515649 
hsa-miR-342-5p  –1.333040563 5.825155044 0.013564947 
hsa-miR-30c  –1.050089726 5.567514099 0.01445844 
hsa-miR-494  –1.125921065 4.652256751 0.033330803 
 
Table 2B. All the differentially expressed miRNAs (DEMs) in peripheral blood 
mononuclear cell samples from long-standing patients with type 1 diabetes mellitus 
(T1DM) compared with those from healthy people (DEMs-long) 
Gene LogFC AveExpr p value 
hsa-miR-378e 
 
–1.194166667 
10.26958333 2.99E-06 
 20 
 
hsa-miR-338-3p 
 
–1.083333333 
6.218333333 1.10E-05 
hsa-miR-26a-5p 
 
–1.019166667 
4.987083333 2.58E-05 
hsa-miR-16-5p 
 
–1.310833333 
7.647083333 0.001228264 
hsa-miR-144-3p 1.811666667 1.316666667 0.025897521 
hsa-miR-451a 
 
–1.174166667 
10.32875 0.031611088 
 
Table IIIA. All the enriched gene ontology (GO) terms of DEGs-short 
Ca
tegory 
Term Gene count p value 
BP 
GO:0042742~defense response to 
bacterium 
6 2.13E-06 
BP GO:0006935~chemotaxis 5 2.40E-04 
CC 
GO:0031226~intrinsic to plasma 
membrane 
7 0.012653662 
MF 
GO:0032393~MHC class I receptor 
activity 
2 0.03693037 
BP GO:0006026~aminoglycan catabolic 2 0.040243639 
 21 
 
process 
CC 
GO:0005887~integral to plasma 
membrane 
6 0.042766631 
DEGs — differentially expressed genes; BP — biological process; CC — cellular 
component; MF — molecular function 
 
Table IIIB. The top 10 most significantly enriched gene ontology (GO) terms of 
DEGs-long 
Categ
ory 
Term Gene Count P Value 
CC GO:0043292~contractile fibre 9 
3.40E-0
7 
CC GO:0044444~cytoplasmic part 46 
3.35E-0
5 
BP GO:0008217~regulation of blood pressure 7 
3.44E-0
5 
CC GO:0030485~smooth muscle contractile fibre 3 
1.81E-0
4 
CC GO:0005737~cytoplasm 57 
3.52E-0
4 
BP GO:0031032~actomyosin structure 4 6.66E-0
 22 
 
organization 4 
CC GO:0031410~cytoplasmic vesicle 12 
7.96E-0
4 
CC GO:0030016~myofibril 5 
0.00335
0748 
BP GO:0030334~regulation of cell migration 6 
0.00389
6976 
BP 
GO:0048738~cardiac muscle tissue 
development 
4 
0.00523
0827 
DEGs — differentially expressed genes; BP — biological process; CC — cellular 
component 
 
Table IVA. The miRNA-gene pairs of DEMs-short 
MicroRNA Gene MicroRNA_logFC Gene_logFC 
hsa-miR-181c TNFAIP6  –1.26274394 1.364051308 
hsa-miR-181c DDX3Y  –1.26274394 1.249616883 
hsa-miR-181c KCNJ2  –1.26274394 1.077869083 
hsa-miR-181a TNFAIP6  –1.887221452 1.364051308 
hsa-miR-181a DDX3Y  –1.887221452 1.249616883 
hsa-miR-181a KCNJ2  –1.887221452 1.077869083 
 23 
 
hsa-miR-146b-5p EIF1AY  –2.666591212 1.9180783 
hsa-miR-146b-5p 
CEACA
M8 
 –2.666591212 1.822226467 
hsa-miR-125b MS4A3  –1.075210791 1.222284567 
hsa-miR-181c KLRF1  –1.26274394 -1.000714933 
hsa-miR-181a KLRF1  –1.887221452 -1.000714933 
hsa-miR-181c IFNG  –1.26274394 -1.060417167 
hsa-miR-181a IFNG  –1.887221452 -1.060417167 
hsa-miR-125b IFNG  –1.075210791 -1.060417167 
hsa-miR-146b-5p FGFBP2  –2.666591212 -1.16267335 
hsa-miR-125b CCL4  –1.075210791 -1.266147883 
hsa-let-7f DUSP2  –1.664920459 -1.289584217 
DEMs — differentially expressed miRNAs 
 
Table IVB. The miRNA-gene pairs of DEMs-long 
MicroRNA Gene MicroRNA_logFC Gene_logFC 
hsa-miR-338-3p CCL21  –1.083333333 2.10357751 
hsa-miR-338-3p CXCL9  –1.083333333 1.77456068 
hsa-miR-338-3p ALDOB  –1.083333333 1.580524957 
 24 
 
hsa-miR-338-3p UTY  –1.083333333 1.428451427 
hsa-miR-338-3p PTGIS  –1.083333333 1.424889976 
hsa-miR-338-3p PRRX1  –1.083333333 1.242794076 
hsa-miR-338-3p TMOD1  –1.083333333 1.196113314 
hsa-miR-338-3p HOXA3  –1.083333333 1.121206093 
hsa-miR-338-3p TFPI  –1.083333333 1.100948365 
hsa-miR-338-3p EIF1AY  –1.083333333 1.08379585 
hsa-miR-338-3p COL12A1  –1.083333333 1.040322198 
hsa-miR-338-3p SYT7  –1.083333333 -1.030068536 
hsa-miR-338-3p RGS16  –1.083333333 -1.031304186 
hsa-miR-338-3p AQP2  –1.083333333 -1.034998067 
hsa-miR-338-3p PPP1R1A  –1.083333333 -1.113167906 
hsa-miR-338-3p UNC5A  –1.083333333 -1.173571 
hsa-miR-338-3p SLC30A8  –1.083333333 -1.494275889 
hsa-miR-338-3p SYT13  –1.083333333 -1.662898167 
hsa-miR-338-3p SLC25A34  –1.083333333 -1.728247111 
hsa-miR-338-3p PCSK1  –1.083333333 -1.979802762 
DEMs — differentially expressed miRNAs 
